News & Updates

Show Multimedia Only

Visual distraction eases pain, anxiety during colonoscopy

02 Oct 2025

Patients undergoing colonoscopy may benefit from visual/audiovisual distraction interventions, which have been shown to reduce pain and anxiety and improve satisfaction during the procedure, suggests a recent study.

Visual distraction eases pain, anxiety during colonoscopy

02 Oct 2025

JAK inhibitor a new hope for new-onset T1D?

02 Oct 2025 by

The 2-year outcomes from the phase II BANDIT* trial confirm the potential of the Janus kinase (JAK) inhibitor baricitinib for the treatment of new-onset type 1 diabetes (T1D).

JAK inhibitor a new hope for new-onset T1D?

02 Oct 2025

Pembrolizumab plus chemo efficacious in advanced PSCC

02 Oct 2025

Treatment with the combination of pembrolizumab plus chemotherapy elicits response in patients with advanced penile squamous cell carcinoma (PSCC) while having a manageable safety profile, according to the phase II HERCULES trial.

Pembrolizumab plus chemo efficacious in advanced PSCC

02 Oct 2025

Antenatal betamethasone lowers risk of respiratory morbidity in late preterm twin neonates

01 Oct 2025

Antenatal administration of betamethasone in women with twin pregnancies at risk of late preterm delivery appears to reduce the risk of neonatal respiratory morbidity, as shown in a study.

Antenatal betamethasone lowers risk of respiratory morbidity in late preterm twin neonates

01 Oct 2025

Extended risankizumab treatment for CD may be needed in some patients

01 Oct 2025 by

For some patients with Crohn’s disease (CD) who show no response to induction treatment with risankizumab, extending the treatment course is safe and improves clinical and endoscopic outcomes, as shown in a study.

Extended risankizumab treatment for CD may be needed in some patients

01 Oct 2025

Brain fog common in patients with GI disorders

01 Oct 2025

Half of the patients with common gastrointestinal (GI) disorders report experiencing brain fog (BF), reveals a study. BF prevalence is higher in patients on probiotics and those with gastroparesis and irritable bowel syndrome (IBS).

Brain fog common in patients with GI disorders

01 Oct 2025

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC

01 Oct 2025 by

Reducing the dose of trastuzumab deruxtecan (T-DXd) does not have any significant effect on real-world (rw) progression-free survival (PFS) or treatment-related toxicities among patients with metastatic breast cancer (MBC), as shown in a Singapore study.

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC

01 Oct 2025

Cognition-guided neurofeedback enhances response inhibition in MUD

01 Oct 2025

Cognition-guided EEG neurofeedback improves response inhibition among men with methamphetamine use disorder (MUD), a study has shown.

Cognition-guided neurofeedback enhances response inhibition in MUD

01 Oct 2025

Long COVID symptoms may persist 3 years post-infection

01 Oct 2025 by

One in five COVID-19 survivors experiences at least one unresolved symptom 3 years after the initial infection, a systematic review and meta-analysis reports.

Long COVID symptoms may persist 3 years post-infection

01 Oct 2025

Poor psychological health highly prevalent in IBD patients

01 Oct 2025

Patients with inflammatory bowel disease (IBD) commonly experience poor psychological health, which point to the possibility that physical inflammation in the gut directly influences psychological state, according to a study.

Poor psychological health highly prevalent in IBD patients

01 Oct 2025

News & Updates

Filter by Specialty:

Specialty:

Visual distraction eases pain, anxiety during colonoscopy

Visual distraction eases pain, anxiety during colonoscopy

JAK inhibitor a new hope for new-onset T1D?

JAK inhibitor a new hope for new-onset T1D?

Pembrolizumab plus chemo efficacious in advanced PSCC

Pembrolizumab plus chemo efficacious in advanced PSCC

Antenatal betamethasone lowers risk of respiratory morbidity in late preterm twin neonates

Antenatal betamethasone lowers risk of respiratory morbidity in late preterm twin neonates

Extended risankizumab treatment for CD may be needed in some patients

Extended risankizumab treatment for CD may be needed in some patients

Brain fog common in patients with GI disorders

Brain fog common in patients with GI disorders

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC

Dose reduction does not limit efficacy of trastuzumab deruxtecan in MBC

Cognition-guided neurofeedback enhances response inhibition in MUD

Cognition-guided neurofeedback enhances response inhibition in MUD

Long COVID symptoms may persist 3 years post-infection

Long COVID symptoms may persist 3 years post-infection

Poor psychological health highly prevalent in IBD patients

Poor psychological health highly prevalent in IBD patients